Effects of excipients on the chemical and physical stability of glucagon during freeze-drying and storage in dried formulations
- PMID: 22766900
- DOI: 10.1007/s11095-012-0820-7
Effects of excipients on the chemical and physical stability of glucagon during freeze-drying and storage in dried formulations
Abstract
Purpose: To evaluate the effects of several buffers and excipients on the stability of glucagon during freeze-drying and storage as dried powder formulations.
Methods: The chemical and physical stability of glucagon in freeze-dried solid formulations was evaluated by a variety of techniques including mass spectrometry (MS), reversed phase HPLC (RP-HPLC), size exclusion HPLC (SE-HPLC), infrared (IR) spectroscopy, differential scanning calorimetry (DSC) and turbidity.
Results: Similar to protein drugs, maintaining the solid amorphous phase by incorporating carbohydrates as well as addition of surfactant protected lyophilized glucagon from degradation during long-term storage. However, different from proteins, maintaining/stabilizing the secondary structure of glucagon was not a prerequisite for its stability.
Conclusions: The formulation lessons learned from studies of freeze-dried formulations of proteins can be applied successfully to development of stable formulations of glucagon. However, peptides may behave differently than proteins due to their small molecule size and less ordered structure.
Similar articles
-
Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.PDA J Pharm Sci Technol. 2015 May-Jun;69(3):399-416. doi: 10.5731/pdajpst.2015.01052. PDA J Pharm Sci Technol. 2015. PMID: 26048746
-
Physical characterisation of formulations for the development of two stable freeze-dried proteins during both dried and liquid storage.Eur J Pharm Biopharm. 2005 Aug;60(3):335-48. doi: 10.1016/j.ejpb.2005.02.013. Eur J Pharm Biopharm. 2005. PMID: 15894475
-
Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.Pharm Res. 2007 Apr;24(4):715-27. doi: 10.1007/s11095-006-9191-2. Epub 2007 Feb 15. Pharm Res. 2007. PMID: 17372697
-
Arginine as an Excipient for Protein Freeze-Drying: A Mini Review.J Pharm Sci. 2018 Apr;107(4):960-967. doi: 10.1016/j.xphs.2017.11.015. Epub 2017 Nov 26. J Pharm Sci. 2018. PMID: 29183741 Review.
-
Applications of Freezing and Freeze-Drying in Pharmaceutical Formulations.Adv Exp Med Biol. 2018;1081:371-383. doi: 10.1007/978-981-13-1244-1_20. Adv Exp Med Biol. 2018. PMID: 30288720 Review.
Cited by
-
Needle-Free Dermal Delivery of a Diphtheria Toxin CRM197 Mutant on Potassium-Doped Hydroxyapatite Microparticles.Clin Vaccine Immunol. 2015 May;22(5):586-92. doi: 10.1128/CVI.00121-15. Epub 2015 Mar 25. Clin Vaccine Immunol. 2015. PMID: 25809632 Free PMC article.
-
Structural transitions and interactions in the early stages of human glucagon amyloid fibrillation.Biophys J. 2015 Feb 17;108(4):937-948. doi: 10.1016/j.bpj.2015.01.004. Biophys J. 2015. PMID: 25692598 Free PMC article.
-
Emergency delivery of particulate drugs by active ejection using in vivo wireless devices.Nat Biomed Eng. 2025 Jul 9. doi: 10.1038/s41551-025-01436-2. Online ahead of print. Nat Biomed Eng. 2025. PMID: 40634646
-
Formulation Factors Affecting the Formation of Visible-Bubbles During the Reconstitution Process of Freeze-Dried Etanercept Formulations: Protein Concentration, Stabilizers, and Surfactants.AAPS J. 2025 Jan 17;27(1):29. doi: 10.1208/s12248-024-01009-2. AAPS J. 2025. PMID: 39825117
-
Synthesis of Zwitterionic and Trehalose Polymers with Variable Degradation Rates and Stabilization of Insulin.Biomacromolecules. 2020 Jun 8;21(6):2147-2154. doi: 10.1021/acs.biomac.0c00133. Epub 2020 May 5. Biomacromolecules. 2020. PMID: 32369347 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical